| Model | Animal | Cell | Type | Major findings | References |
| Laparotomy | Mice | — | In vivo | TNF-α↓, IL-1β↓, IL-6↓, IL-10↑, Prx↓ | [58] M. Xiaona, et al 2017 | MCAO/H2O2 | Rat | SH-SY5Y | In vivo/In vitro | TLR4↓, NF-κB↓, neuron loss↓, astrocyte and microglia/macrophage activation↓, T-lymphocyte invasion↓, lipid peroxidation↓ | [61]Zhang HS, et al 2021 | TCDD | | C6 | In vitro | TNF-α↓, IL-6↓, iNOS↓, GFAP↓, SSeCKS-TRAF6 interaction↓、NF-κB↓ | [62]Jiao M, et al2019 | Glutamate | - | HT-22 | In vitro | ROS↓, Nrf2 nuclear translocation↑, HO-1↑ | [65]Jiang T,et al2020 | MCAO | Mice | — | In vivo | Bcl - 2↑, Bax↓, MDA↓ SOD↑, HO-1↑, Nrf2↑ | [67]Peng Z,et al 2015 | ICH | Rat | — | In vivo | ROS↓, MDA↓, GSH-Px↑, Keap1↑, Nrf2↑, HO-1↑, caspase-3↓, caspase-9↓ | [68]Liu X,et al 2020 | Pb exposed | Mice | — | In vivo | p-tau↓, Aβ↓, COX-2↓, NR2A, BDNF, Bax↓, Nrf2↑, Wnt/β-catenin↑ | [69]Liu C-M,et al 2020 | APP/PS1/Aβ(1–42) | Rat | SH-SY5Y | In vivo/In vitro | Aβ plaques↓, hyperphosphorylated tau↓, enzymes of Aβ↓, GSK3β↓ | [74]YQ Zeng,et al2021 | MCAO | Rat | — | In vivo | LC3↓, p62↓, phosphorylated CaMKII↓, autophagic flux↓, Ca2+↓ | [77]Chen T-T,et al2021 | Glutamate | — | PC12 | In vitro | MMP↓, Ca2+ influx↓, CaMKII↓, ASK-1↓, p38 MAPK↓, p53↓、cytochrome C↓, | [78]Jiang G,et al2014 | Kainic acid | — | NSC | In vitro | astrocytes↓, neurons↑ | [82]Sun G,et al2012 | MA | — | PCNC | In vitro | CAMP↑, pPKA↑, pCREB↑, BDNF↑ | [83]CL M,et al2020 | BCCAO/OGD/R | Mice | HNSCs | In vivo/In vitro | PDE9↓, cGMP-PKG↑, cell viability↑, proliferation in primary hippocampal NSCs↑ | [85]H. Xiao,et al2021 | Aβ (1–42) | C57BL/6 | — | In vivo | SOX-2 and DCX cells in the DG area↑ | [86]Li M,et al2016 | MCAO | Rat | BV-2 | In vivo/In vitro | MMP2↓, MMP9↓, neurological scores↑, the area of cerebral infarction↓ | [88]Li S,et al2019 | LPS | — | BV-2 | In vitro | iNOS↓, COX-2↓, NF-κB↓, CRE-CREB↓, ERK1/2↓, JNK↓, p38MAPK↓ | [90]Dai J-N,et al 2011 | OGD | | BV2 | In vitro | Death rate of BV-2 cells↓, several proteins which can affect the MAPK↑ | [91]Xia L,et al2014 | OGD | — | BV2 | In vitro | Inflammatory cytokines↓, protective cytokines↑ | [92]Lv Y,et al2021 | LPS | Rat | BV-2 | In vivo/In vitro | Notch-1↑, NICD↑, RBP-Jκ↑, Hes-1↑, Notch-1/Sirt3 | [93]G. J,et al2021 | LPS | Rat | BV-2 | In vivo/In vitro | NICD↓, RBP-Jκ↓, Hes-1↓, ERK, JNK, P38, | [94]Yao Y,et al2021 | LPS | Rat | BV-2 | In vivo/In vitro | ACE↓, AT1↓, NOX-2↓, iNOS↓, TNF-α↓, AT2↑, SIRT3↑ | [95]Liu SJ,et al2018 | Aβ(1–42) | — | HNC | In vitro | CAT↓, SOD↓, ERKl/2↓ | [52]Zhao X,et al2012 | MCAO | Mice | — | In vivo | DCX/BrdU double-positive cells↑, infarct volume↓, apoptosis↓, wnt/β-catenin↑ | [98]Qiu CW,et al2019 | LPS | — | BV-2 | In vitro | Phosphorylation of GSK-3β at ser 9 and β-catenin activity↓ | [99]Yao Y yi,et al2019 | MCAO/OGD | Rat | TNA2 | In vivo/In vitro | p-STAT3↓, NLRP3↓, NLRC4↓, caspase-1↓, IL-18↓, NF-κb↓ | [100]Sui Y,et al2019 |
|
|